Compare Aurora Cannabis Inc (ACB) vs Air Products & Chemicals, Inc. (APD) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

APD trades at $305.05, down 2.91% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, though 2025 saw a net loss of $394.50 million. Recent strategic moves include exiting the Louisiana Clean Energy Complex and finalizing a renewable ammonia deal with Yara, signaling a refined growth focus.

The outlook is positive with a consensus price target of $324.89, implying 6.5% upside. Risks include high debt levels and volatile cash flows from heavy investments. Investors should weigh the company's long-term growth projects against near-term financial pressures and geopolitical uncertainties affecting supply chains.